Meeting the challenges of PET-based molecular imaging in cancer

Expert Review of Molecular Diagnostics

Volumn 13, Issue 7, 2013, Pages 671-680

  Choyke, Peter ^a   Kurdziel, Karen A ^a   Mena, Esther ^a   Lindenberg, Maria L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; FLT; Fluoro L thymidine; Fluorodeoxyglucose; Ionizing radiation; Medical costs; Molecular imaging; PET; Positron emission tomography; Regulations; Single photon emission computed tomography; SPECT

Indexed keywords

3' FLUOROTHYMIDINE F 18; ACETIC ACID C 11; CA 125 ANTIGEN; CARBON 11; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; COPPER 64; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; FLUOROURACIL; IBRITUMOMAB TIUXETAN; METHIONINE C 11; NITROGEN 13; PACLITAXEL; PLERIXAFOR; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM 86; DIAGNOSTIC AGENT;

AMINO ACID TRANSPORT; BREAST CANCER; CANCER DIAGNOSIS; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DRUG UPTAKE; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HEALTH CARE COST; HUMAN; IONIZING RADIATION; ISOTOPE LABELING; LYMPHOMA; MOLECULAR IMAGING; NEOPLASM; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REIMBURSEMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL; TREATMENT RESPONSE; ARTICLE; METHODOLOGY; SCINTISCANNING; DIAGNOSTIC USE; PROCEDURES;

HUMANS; MOLECULAR IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84898697027     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2013.835568     Document Type: Conference Paper

References (39)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
2. Vogelstein B. Genetic testings for cancer: the surgeon's critical role. Familial colon cancer. J. Am. Coll. Surg. 188(1), 74-79 (1999).
3. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012).
4. Chang MC, Malowany JI, Mazurkiewicz J, Wood M. 'Genetic heterogeneity' in HER2/ neu testing by fluorescence in situ hybridization: a study of 2,522 cases. Mod. Pathol. 25(5), 683-688 (2012).
5. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Sem. Oncol. 27(5 Suppl. 9), 13-19 (2000).
6. Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, Pomper MG. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res. 70(10), 3935-3944 (2010).
7. Conti PS, McEwan AJ, Pomper MG. Molecular imaging: the future of modern medicine. J. Nucl. Med. 49(6), 16N-20N (2008).
8. Pomper MG. Translational molecular imaging for cancer. Cancer Imaging S16-S26 (2005).
9. Bensinger S, Christofk H. New aspects of the Warburg effect in cancer cell biology. Semin. Cell Dev. Biol. 23(4), 352-361 (2012).
10. Drzezga A, Souvatzoglou M, Eiber M et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/ CT in patients with oncologic diagnoses. J. Nucl. Med. 53(6), 845-855 (2012).
11. Ribom D, Engler H, Blomquist E, Smits A. Potential significance of (11)C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur. J. Nucl. Med. Mol. Imaging 29(5), 632-640 (2002).
12. McConathy J, Yu W, Jarkas N, Seo W, Schuster DM, Goodman MM. Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents. Med. Res. Rev. 32(4), 868-905 (2012).
13. Schuster DM, Nye JA, Nieh PT et al. Initial experience with the radiotracer anti- 1-amino-3-[18F]Fluorocyclobutane-1- carboxylic acid (anti-[ 18F]FACBC) with PET in renal carcinoma. Mol. Imaging Biol. 11(6), 434-438 (2009).
14. Grassi I, Nanni C, Allegri V et al. The clinical use of PET with (11)C-acetate. Am. J. Nucl. Med. Mol. Imaging 2(1), 33-47 (2012).
15. Albrecht S, Buchegger F, Soloviev D et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur. J. Nucl. Med. Mol. Imaging 34(2), 185-196 (2007).
16. Jacobs AH, Thomas A, Kracht LW et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J. Nucl. Med. 46(12), 1948-1958 (2005).
17. Linden HM, Kurland BF, Peterson LM et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin. Cancer Res. 17(14), 4799-4805 (2011).
18. Beattie BJ, Smith-Jones PM, Jhanwar YS et al. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alphadihydrotestosterone (FDHT) in prostate tumors as measured by PET. J. Nucl. Med. 51(2), 183-192 (2010).
19. Larson SM, Morris M, Gunther I et al. Tumor localization of 16beta-18F-fluoro- 5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med. 45(3), 366-373 (2004).
20. Bander NH, Trabulsi EJ, Kostakoglu L et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. 170(5), 1717-1721 (2003).
21. Perik PJ, Lub-De Hooge MN, Gietema JA et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 24(15), 2276-2282 (2006).
22. Tomasi G, Kenny L, Mauri F, Turkheimer F, Aboagye EO. Quantification of receptor-ligand binding with [(1)(8)F] fluciclatide in metastatic breast cancer patients. Eur. J. Nucl. Med. Mol. Imaging 38(12), 2186-2197 (2011).
23. Wu AM. Engineering multivalent antibody fragments for in vivo targeting. Methods Mol. Biol. 248, 209-225 (2004).
24. De Saint-Hubert M, Bauwens M, Verbruggen A, Mottaghy FM. Apoptosis imaging to monitor cancer therapy: the road to fast treatment evaluation? Curr. Pharm. Biotechnol. 13(4), 571-583 (2012).
25. Jacobson O, Weiss ID, Szajek LP et al. PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics 1, 251-262 (2011).
26. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 83(2), 245-253 (1998).
27. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J. Nucl. Med. 39(7), 1197-1202 (1998).
28. Ginos JZ, Cooper AJ, Dhawan V et al. [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J. Nucl. Med. 28(12), 1844-1852 (1987).
29. De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J. Nucl. Med. 52(6), 986-993 (2011).
30. Jacobson O, Weiss ID, Szajek L, Farber JM, Kiesewetter DO. 64Cu-AMD3100-a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg. Med. Chem. 17(4), 1486-1493 (2009).
31. Cho SY, Gage KL, Mease RC et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J. Nucl. Med. 53(12), 1883-1891 (2012).
32. Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur. J. Nucl. Med. Mol. Imaging 40(6), 819-823 (2013).
33. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 33(10), 1115-1122 (2006).
34. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Macke HR, Eisenhut M, Strauss LG. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J. Nucl. Med. 48(8), 1245-1250 (2007).
35. Thomas CT, Bradshaw PT, Pollock BH et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J. Clin. Oncol. 21(9), 1715-1721 (2003).
36. Nagda SN, Mohideen N, Lo SS et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 67(3), 834-840. (2007).
37. Troyer JK, Feng Q, Beckett ML, Wright GL Jr. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol. Oncol. 1(1), 29-37 (1995).
38. Shan L. Gallium-68-dotamaleimide-Cys2- annexin A5. In: Molecular Imaging and Contrast Agent Database (MICAD). National Center for Biotechnology Information (US), Bethesda, MD, USA, 2004-2013 (2011).
39. Administration FaHHSD. Current good manufacturing practice for positron emission tomography drugs. Fed. Regist. 74(236), 65409-65436 (2009).